Interstrand cross-links of cisplatin induce striking distortions in DNA

Journal of Inorganic Biochemistry

Volumn 77, Issue 1-2, 1999, Pages 23-29

  Malinge, Jean Marc ^a   Giraud Panis, Marie Josèphe ^a   Leng, Marc ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

Cisplatin; DNA distortion; Interstrand cross links

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; CARBOPLATIN; CISPLATIN; TRANSPLATIN;

ARTICLE; CHEMICAL STRUCTURE; CROSS LINKING; CRYSTAL STRUCTURE; DNA DRUG COMPLEX; DNA STRUCTURE; DRUG CROSS REACTIVITY; DRUG STABILITY;

CISPLATIN; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; FEMALE; HUMANS; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; PREGNANCY;

EID: 0033368914     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-0134(99)00148-8     Document Type: Article

References (62)

1. P.J. O'Dwyer, J.P. Stevenson, S.W. Johnson, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Clinical Status of Cisplatin, Carboplatin, and Other Platinum-Based Antitumor Drugs, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 31-69.
2. A. Eastman, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, The Mechanism of Action of Cisplatin: From Adducts to Apoptosis, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 111-134.
3. Eastman A. Pharmacol. Ther. 34:1987;155-166.
4. Reedijk J. Inorg. Chim. Acta. 873:1992;198-200.
5. K.M. Comess, S.J. Lippard, in: S. Neidle, M. Waring (Eds.), Molecular Aspects of Anti-Cancer-Drug-DNA Interactions, vol. 1, Molecular Aspects of Platinum-DNA Interactions, Macmillan, London, 1993, pp. 134-168.
6. Frit P., Calsou P., Canitrot Y., Muller C., Salles B. Anticancer Drugs. 7:1996;101-108.
7. Chu G. J. Biol. Chem. 269:1994;787-790.
8. Henkels K.M., Turchi J.J. Cancer Res. 57:1997;4488-4492.
9. C.A. Lepre, S.J. Lippard, in: F. Eckstein, D.M.J. Lilley (Eds.) Nucleic Acids and Molecular Biology, vol. 4, Interaction of Platinum Antitumor Compounds with DNA, Springer, Berlin, 1990, pp. 9-38.
10. M. Sip, M. Leng, in: F. Eckstein, D.M.J. Lilley (Eds.), Nucleic Acids and Molecular Biology, vol. 7, cis-Platinum and Intercalators: Catalytic Activity of the DNA Double Helix, Springer, Berlin, 1993, pp. 1-15.
11. M.J. Bloemink, J. Reedijk, in: A. Sigel, H. Sigel (Eds.), Metal Ions in Biological Systems, vol. 32, Cisplatin and Derived Anticancer Drugs: Mechanism and Current Status of DNA Binding, Marcel Dekker, New York, 1996, pp. 641-685.
12. Fichtinger-Shepman A.M., van de Veer J.L., Lohman P.H., Reedijk J. Biochemistry. 24:1985;707-713.
13. D.B. Zamble, S.J. Lippard, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, The Response of Cellular Proteins to Cisplatin-Damaged DNA, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 73-110.
14. Roberts J.J., Friedlos F. Pharmacol. Ther. 34:1987;215-246.
15. J.J. Roberts, R.J. Knox, M.F. Pera, F. Fiedlos, P.A. Lydall, in: M. Nicolini (Ed.), Platinum and Other Coordination Compounds in Cancer Chemotherapy, Nijhoff, Boston, 1988, pp. 16-31.
16. Corda Y., Job C., Anin M.F., Leng M., Job D. Biochemistry. 32:1993;8582-8588.
17. Ali-Osman F., Berger M.S., Rajagopal S., Spence A., Livingston R.B. Cancer Res. 53:1993;5663-5668.
18. Zhen W., Link J.C., O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Mol. Cell. Biol. 12:1992;3689-3698.
19. Larminat F., Zhen W., Bohr V.A. J. Biol. Chem. 268:1993;2649-2654.
20. Johnson S.W., Swiggard P.A., Handel L.M., Brennan J.M., Godwin A.K., Ozols R.F., Hamilton T.C. Cancer Res. 54:1994;5911-5916.
21. Petersen L.N., Mamenta E.L., Stevnsner T., Chaney S.G., Bohr V.A. Carcinogenesis. 17:1996;2597-2602.
22. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Cancer Res. 46:1986;1972-1979.
23. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., Juniewicz P. Mol. Pharmacol. 54:1998;770-777.
24. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. Br. J. Cancer. 77:1998;366-373.
25. Roberts J.J., Pascoe J.M. Nature. 235:1972;282-284.
26. Pera M.F., Rawlings C.J., Shackleton J., Roberts J.J. Biochim. Biophys. Acta. 655:1981;152-166.
27. Hanson J., Wood R.D. Nucleic Acids Res. 17:1989;8073-8091.
28. Brabec V., Leng M. Proc. Natl. Acad. Sci. USA. 90:1993;5345-5349.
29. Jones J.C., Zhen W., Reed E., Parker R.J., Sancar A., Bohr V.A. J. Biol. Chem. 266:1991;7101-7107.
30. Pérez C., Leng M., Malinge J.-M. Nucleic Acids Res. 25:1997;896-903.
31. Eastman A. Biochemistry. 24:1985;5027-5032.
32. Lemaire M.A., Schwartz A., Rahmouni A.R., Leng M. Proc. Natl. Acad. Sci. USA. 88:1991;1982-1985.
33. Hopkins P.B., Millard J.T., Woo J., Weidner M.F., Kirchner J.J., Sigurdsson S.T., Raucher S. Tetrahedron. 47:1991;2475-2489.
34. 15N-NMR Spectroscopic Studies of Cisplatin Reactions with Biomolecules, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 293-318.
35. L.A. Zwelling, in: J. Arnold (Ed.), Metal Chemotherapeutic Agents, Biological Consequences of Platinum-DNA cross-links in Mammalian Cells, ACS Symposium Series, American Chemical Society, Washington, DC, 1983, pp. 27-49.
36. Micetich K., Zwelling L.A., Kohn K.W. Cancer Res. 43:1983;3609-3613.
37. Payet D., Gaucheron F., Sip M., Leng M. Nucleic Acids Res. 21:1993;5846-5851.
38. Davies M.S., Berners-Price S.J., Hambley T.W. J. Am. Chem. Soc. 120:1998;11380-11390.
39. F. Legendre, J.-C. Chottard, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Kinetics and Selectivity of DNA-Platination, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 223-245.
40. Reeder F., Gonnet F., Kozelka J., Chottard J.-C. Chem. Eur. J. 2:1996;1068-1076.
41. Vrána O., Boudný V., Brabec V. Nucleic Acids Res. 24:1996;3918-3925.
42. Yang D., Wang A. H.-J. Prog. Biophys. Mol. Biol. 66:1996;81-111.
43. Sip M., Schwartz A., Vovelle F., Ptak M., Leng M. Biochemistry. 31:1992;2508-2513.
44. Schwartz A., Leng M. J. Mol. Biol. 236:1994;969-974.
45. Malinge J.-M., Pérez C., Leng M. Nucleic Acids Res. 22:1994;3834-3839.
46. Huang H., Zhu L., Reid B.R., Drobny G.P., Hopkins P.B. Science. 270:1995;1842-1845.
47. Paquet F., Pérez C., Leng M., Lancelot G., Malinge J.-M. J. Biomol. Struct. Dyn. 14:1996;67-77.
48. Coste F., Malinge J.-M., Serre L., Sheppard W., Roth M., Leng M., Zelwer C. Nucleic Acids Res. 27:1999;1837-1846.
49. Dornberger U., Leijon M., Fritzsche H. J. Biol. Chem. 274:1999;6957-6962.
50. Brabec V., Reedijk J., Leng M. Biochemistry. 31:1992;12397-12402.
51. Brabec V., Boudný V., Balcarová Z. Biochemistry. 33:1994;1316-1322.
52. Barrett T.E., Savva R., Barlow T., Brown T., Jiricny J., Pearl L.H. Nature Struct. Biol. 5:1998;697-701.
53. E.C. Friedberg, G.C. Walker, W. Siede, DNA Repair and Mutagenesis, ASM Press, Washington, DC, 1995.
54. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Biochemistry. 35:1996;10004-10013.
55. Bessho T., Mu D., Sancar A. Mol. Cell. Biol. 17:1997;6822-6830.
56. Heiger-Bernays W.J., Essigmann J.M., Lippard S.J. Biochemistry. 29:1990;8461-8466.
57. Boudvillain M., Dalbiès R., Aussourd C., Leng M. Nucleic Acids Res. 23:1995;2381-2388.
58. J.-M. Malinge, M. Leng, in: B. Lippert (Ed.), Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug, Interstrand Cross-Links in Cisplatin- or Transplatin-Modified DNA, V.H.C.A., Wiley-VCH, Zurich, 1999, pp. 159-180.
59. F. Paquet, M. Boudvillain, G. Lancelot, M. Leng, Nucleic Acids Res. (1999) in press.
60. Kasparkova J., Brabec V. Biochemistry. 34:1995;12379-12387.
61. Reed E., Ozols R.F., Tarone R., Yuspa S.H., Poirier M.C. Proc. Natl. Acad. Sci. USA. 84:1987;5024-5028.
62. Hartley J.M., Spanswick V.J., Gander M., Giacomini G., Whelan J., Souhami R.L., Hartley J.A. Clin. Cancer Res. 5:1999;507-512.